Achillion Pharma

@AchillionPharma

On January 28, 2020, Achillion was acquired by Alexion Pharmaceuticals, Inc. For more information, please visit .

New Haven, CT
Vrijeme pridruživanja: ožujak 2011.

Tweetovi

Blokirali ste korisnika/cu @AchillionPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AchillionPharma

  1. Prikvačeni tweet
    28. sij

    Pleased to share that Achillion has been acquired by . As part of Alexion, we remain driven to transform the lives of people and families affected by diseases of the complement system.

    Poništi
  2. 10. pro 2019.
    Poništi
  3. 9. pro 2019.

    Today, announced positive top-line results for danicopan (ACH-4471) from the Phase 2 combination therapy trial with eculizumab at . Be sure to check out the details here:

    Poništi
  4. 19. stu 2019.

    is pleased to announce today that the EMA grants PRIME (Priority Medicines) designation to danicopan (ACH-4471) for treatment of patients who are not adequately responding to a C5 inhibitor.

    Poništi
  5. 11. stu 2019.

    Today and every day, we honor those who bravely served our country.

    Poništi
  6. 11. stu 2019.

    Today, announced that the US FDA has accepted the Investigational New Drug Application (IND) for ACH-5228, our second-generation oral factor D inhibitor. See the press release for more detail:

    Poništi
  7. 7. stu 2019.

    Today, reported third quarter 2019 financial results and provided a corporate update. See the press release for more detail:

    Poništi
  8. 6. stu 2019.

    We are pleased to announce today the acceptance of two abstracts for poster presentation at of P2 clinical data for our lead investigational oral factor D inhibitor, danicopan (ACH-4471). Check out the press release for more details:

    Poništi
  9. 16. lis 2019.

    to be acquired by , accelerating our objective of bringing novel therapies to market faster to improve lives of patients. For important information read here:

    Poništi
  10. 26. ruj 2019.

    Mark your calendars! ’s CEO, Joseph Truitt, will be presenting at the 2019 Cantor Fitzgerald Global Healthcare Conference on October 3rd at 8:55 a.m. ET

    Poništi
  11. 25. ruj 2019.

    is pleased to announce that the FDA has granted Breakthrough Therapy Designation for danicopan (ACH-4471) in combination with a C5 monoclonal antibody for the treatment of patients with who are sub-optimal responders to a C5 inhibitor alone.

    Poništi
  12. 30. kol 2019.

    ’s CEO, Joseph Truitt, will be presenting at the Baird 2019 Global Healthcare Conference on September 5th!

    Poništi
  13. 8. kol 2019.

    Today, reported second quarter 2019 financial results and provided a corporate update. See the PR for more detail:

    Poništi
  14. 22. srp 2019.

    Be sure to check out ’s July corporate presentation including new topline Ph1 multiple ascending dose study data for ACH-5228 in healthy volunteers, our investigational next-gen oral factor D inhibitor

    Poništi
  15. 22. srp 2019.

    Today we announced positive results for ACH-5228, our investigational next-gen oral factor D inhibitor, from the Ph1 multiple ascending dose study in healthy volunteers. Check out the official PR for more detail:

    Poništi
  16. 4. srp 2019.

    Wishing you all a safe and happy from the team!

    Poništi
  17. 20. lip 2019.

    Don’t forget to check out ’s presentation at the 2019 JMP Securities Life Sciences Conference. Watch the live webcast:

    Poništi
  18. 17. lip 2019.

    It was great connecting with the community at . In case you missed the oral presentation on our investigational treatment danicopan (formerly ACH-4471) in untreated patients, you can find it here:

    Poništi
  19. 14. lip 2019.

    If you’re in attendance, don’t forget to check out the oral presentation tomorrow from ’s Phase 2 data in untreated patients at .

    Poništi
  20. 13. lip 2019.

    ’s CFO and CMO will be presenting at the 2019 JMP Securities Life Sciences Conference on June 20th.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·